Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix
This article was originally published in The Gray Sheet
GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.
You may also be interested in...
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.